Sidley, Goodwin Lead $1.1B Take-Private Deal For Esperion
By Jade Martinez-Pogue · May 1, 2026, 3:18 PM EDT
Biopharmaceutical company Esperion Therapeutics, advised by Goodwin Procter LLP, on Friday announced plans to go private after being bought by Sidley Austin LLP-led healthcare-focused investment firm Archimed in a $1.1 billion...
To view the full article, register now.